Latest:
Dr. Dunavin on Ongoing Research for Myelofibrosis Treatments
Neil Dunavin, MD, MS, discusses ongoing research on therapies for patients with myelofibrosis.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Neil Horowitz, MD
Latest:
Dr. Horowitz on Frontline Strategies in Newly Diagnosed Ovarian Cancer
Neil Horowitz, MD, director of Clinical Research in Gynecologic Oncology, assistant professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Dana-Farber Cancer Institute, discusses frontline strategies in the treatment of patients with newly diagnosed advanced ovarian cancer.
Neil L. Berinstein, MD
Latest:
Dr. Berinstein on Combination Treatments for High-Risk and Recurrent Follicular Lymphoma
Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.
Neil P. Shah, MD, PhD
Latest:
Dr. Shah on TKI Treatment Discontinuation in CML
Neil P. Shah, MD, PhD, professor of medicine, Division of Hematology and Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses TKI treatment discontinuation in patients with chronic myeloid leukemia.
Neil S. Wenger, MD, MPH
Latest:
Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors
For a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.
Neil Steers, PhD
Latest:
Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors
For a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.
Nelson Jen An Chao, MD
Latest:
Dr. Chao on Minimal Residual Disease in ALL
Nelson Jen An Chao, MD, professor of medicine, Donald D. and Elizabeth G. Cooke Cancer Research Professor, chief, Division of Cell Therapy in the Department of Medicine, Duke Cancer Institute, discusses minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL).
Nicholas Aksu
Latest:
Where Sipuleucel-T Fits in the Treatment of mCRPC
Sipuleucel-T received an FDA approval in 2010 and a subsequent CMS coverage decision in 2011. At Lancaster Urology in Pennsylvania, we began infusing sipuleucel-T in 2011, and at the 7-year mark, we conducted a review to evaluate these first years of therapy.
Nicholas Butowski, MD
Latest:
Dr. Butowski Discusses Dianhydrogalactitol in Patients with Recurrent GBM
Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I/II study of dianhydrogalacitol in patients with recurrent glioblastoma multiforme (GBM).
Nicholas G. Cost, MD
Latest:
Dr. Cost on Pembrolizumab Plus Axitinib in Patients With RCC
Nicholas G. Cost, MD, assistant professor, Surgery-Urology, Department of Pediatric Urology/ Urologic Oncology, University of Colorado Denver, discusses a clinical trial exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).
Nicholas J. Vogelzang, MD
Latest:
Updates in Genitourinary, Gynecologic Cancers From ASCO 2021: Drs Nick Vogelzang and Erin Crane
OncLive sits down with Nicholas J. Vogelzang, MD, and Erin K. Crane, MD, MPH to discuss the biggest abstracts in genitourinary cancers and gynecologic cancers, respectively, at the 2021 ASCO Annual Meeting.